China
Africa
Explore chapters and articles related to this topic
Liver transplantation
Published in Mark Davenport, James D. Geiger, Nigel J. Hall, Steven S. Rothenberg, Operative Pediatric Surgery, 2020
Caroline Lemoine, Riccardo A. Superina
Hepatocellular carcinoma occurs less frequently than hepatoblastoma in children, and occurs most often in non-cirrhotic livers, in contrast to adults. It is a more aggressive tumor than hepatoblastoma, is usually found to be chemoresistant, and is associated with a worse prognosis. LT appears to offer a higher survival rate (∼70%) than primary resection (30–50%) in children.
Pediatric Oncology
Published in Pat Price, Karol Sikora, Treatment of Cancer, 2020
Stephen Lowis, Rachel Cox, John Moppett, Helen Rees
Hepatoblastoma is the most common childhood liver cancer, with an incidence worldwide of 0.5–1.5 cases per million under the age 15 years.119 Hepatoblastoma occurs most commonly under 3 years and most cases are sporadic. There are known associations with Beckwith–Wiedemann syndrome, familial adenomatous polyposis, Gardner syndrome, and with prematurity and low birth weight.119,120
Familial Adenomatous Polyposis
Published in Dongyou Liu, Handbook of Tumor Syndromes, 2020
Mariann Unhjem Wiik, Bente A. Talseth-Palmer
Individuals affected with classic FAP have 750–7500 times higher risk of developing hepatoblastoma than the general population [4]. However, the absolute risk is estimated to be 1%–2%, and most of the hepatoblastomas occur during the first 5 years of life [2,4,20].
Yap Expression Is Closely Related to Tumor Angiogenesis and Poor Prognosis in Hepatoblastoma
Published in Fetal and Pediatric Pathology, 2022
Wenchen Gong, Zhiqiang Han, Feng Fang, Lu Chen
Hepatoblastoma (HB) is a kind of malignant embryonal tumor with multiple differentiation patterns that accounts for 50%−60% of malignant liver tumors in infants and young children [1,2]. The early symptoms of hepatoblastoma are not obvious, and the disease is often not diagnosed until it invades multiple liver segments or forms an obvious abdominal tumor [3]. A considerable number of children with hepatoblastoma experience vascular invasions, distant metastasis and even tumor rupture. In recent years, the prognosis of patients with hepatoblastoma has improved to some extent due to the optimized combination of liver tumor resection and chemotherapy, as well as the development of individualized preoperative and postoperative chemotherapy [4]; however, the prognosis of children with hepatoblastoma still significantly varies from person to person. Once metastasis occurs, it significantly affects the prognosis of children [5]. Further studies are still needed of the molecular mechanisms of hepatoblastoma development and metastases.
Percutaneous thermal ablation versus open liver resection for recurrent hepatoblastoma: a retrospective study
Published in International Journal of Hyperthermia, 2021
Si-tong Chen, Zhi-yu Han, Ping Ling, Xiao-ling Yu, Zhi-gang Cheng, Fang-yi Liu, Hong Jiang, Jie Yu
Hepatoblastoma (HB) mostly occurs in children younger than three years of age and is the most common primary pediatric liver malignancy [1,2]. In recent years, with the use of cisplatin-based chemotherapy, the prognosis of patients with HB has been significantly improved, and the five-year overall survival (OS) rate has increased from 30% to 80% [3]. Although this is an inspiring result, the prognosis of HB patients who relapse is still unsatisfactory. According to the International Childhood Liver Tumors Strategy Group (SIOPEL), the three-year event-free survival (EFS) and OS rates of patients with recurrent HB are only 34% and 43%, respectively [4]. Therefore, the identification of a suitable and effective treatment to improve the prognosis of relapsed patients is an urgent need.
Imaging and Pathology Study of the Chemotherapy Regression Area of Hepatoblastoma – A Prospective Single-Center Study
Published in Fetal and Pediatric Pathology, 2020
Gang Shen, Linlin Wu, Jie Zhao, Bin Wei, Xianjun Zhou, Xiaoying Zhuo, Qian Dong
Hepatoblastoma is the most common hepatic malignancy in children. It accounts for 50–60% of primary malignant tumors in the liver, 25–45% of all liver tumors, and 1% of all pediatric malignancies. The treatment of hepatoblastoma relies on a multidisciplinary treatment approach based on surgery. The image-based PRETEXT and POST-TEXT staging systems and the clinically and pathologically based COG staging system [1] can provide tremendous assistance toward decision-making in terms of correct treatment options [2, 3]. Thanks to collaborative research by pediatric liver tumor doctors globally and to the continuous advancement of surgical instruments and techniques, the long-term survival rate for hepatoblastoma has been greatly improved [4].